Ovoca Bio PLC traded at 10.25 this Monday March 2nd. Looking back, over the last four weeks, Ovoca Bio lost 86.36 percent. Over the last 12 months, its price rose by 144.05 percent. Looking ahead, we forecast Ovoca Bio PLC to be priced at 9.94 by the end of this quarter and at 9.07 in one year, according to Trading Economics global macro models projections and analysts expectations.
Ovoca Bio plc is a clinical-stage biopharmaceutical company focused on women's health. The Company is developing a treatment for premenopausal women with hypoactive sexual desire disorder (HSDD). It is focused on women's health and identifying candidates in areas of unmet medical need. The Company's lead product, Orenetide (BP-101), is a synthetic peptide administered through nasal spray. The spray delivers the drug to the olfactory and trigeminal nerves in the nasal cavity, where the drug accumulates in the olfactory bulb and further in the brain. It is developing a new treatment for women affected by low libido or sex drive. The Company's subsidiaries include Silver Star Ltd., Bulun LLC, Magsel LLC, IVIX LLC, and OVB (Australia) Pty Ltd, among others. The Company operates in Ireland, the United Kingdom and Russia.